JCT  Vol.5 No.3 , March 2014
Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer
ABSTRACT

Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy in elderly patients with non-small cell lung cancer. Methods: Seventy-four patients (GC regimen, n = 44; PC regimen, n= 30) received gemcitabine at a dose of 1000 mg/m2 on days 1 and 8, and carboplatin with the target dose of area under the curve (AUC) of 4 on day 8 every 28 days and paclitaxel at a dose of 70 mg/m2 on days 1, 8 and 15, and carboplatin with the target dose of AUC of 5 on day 1 every 28 days. Patients were divided in two groups (younger one: n = 42, <70 years old; elderly one: n= 32, ≥70 years old). Results: A total of 222 cycles of the treatment wasadministered. Seventy-one patients (95.9%) completed the scheduled cycles. Two patients in the elderly group were discontinued (6.3%) due to hematological toxicity and melena in the GC regimen and to grade 4 pneumonia in the PC regimen. The dose was reduced in 8 patients (10.8%) due to grade 4 thrombocytopenia. Grade 3/4 neutropenia was not significantly observed in both groups (younger group: 24/42, 57.1%; elderly group: 19/32, 59.4%, p = 0.8471). The nonhematological toxicities were mild in both groups. However, in theelderly group, grade 3/4 thrombocytopenia was significantly observed in the GC group (GC: 5/17, 29.4%; PC: 0/15, 0.0%, p = 0.0222). There was no treatment-related death. Conclusion: These results demonstrate that the GC and PC combination chemotherapies are efficacious and feasible regimens for lung cancer therapy, especially, both regimens should be considered as one of the standard therapies for elderly patients during lung cancer therapy.


Cite this paper
Ayabe, T. , Tomita, M. , Chosa, E. , Ikenoue, M. , Shirasaki, Y. and Nakamura, K. (2014) Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 5, 281-296. doi: 10.4236/jct.2014.53035.
References
[1]   Owonikoko, T.K., Ragin, C.C., Belani, C.P., Oton, A.B., Gooding, W.E., Taioli, E. and Ramalingam, S.S. (2007) Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 25, 5570-5577. http://dx.doi.org/10.1200/JCO.2007. 12.5435

[2]   National Institute of Population and Social Security Research (2005) Population Projections for Japan. 2001-2050. http://www.ipss.go.jp

[3]   Gridelli, C. and Shepherd, F.A. (2005) Chemotherapy for Elderly Patients with Non-Small Cell Lung Cancer: A Review of the Evidence. Chest, 128, 947-957. http://dx.doi.org/10.1378/chest.128.2.947

[4]   Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Data on Individual Patients from 52 Randomised Clinical Trials. BMJ, 311, 899-909. http://dx.doi.org/10.1136/bmj.311.7010.899

[5]   Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D.H. (2002) Eastern Cooperative Oncology Group. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 92-98. http://dx.doi.org/10.1056/NEJMoa011954

[6]   Kubota, K., Nishiwaki, Y., Ohashi, Y., Saijo, N., Ohe, Y., Tamura, T., Negoro, S., Ariyoshi, Y., Nakagawa, K. and Fukuoka, M. (2004) The Four-Arm Cooperative Study (FACS) for Advanced Non-Small-Cell Lung Cancer (NSCLC). Proceeding of the American Society of Clinical Oncology, 22, 14S.

[7]   Hutchins, L.F., Unger, J.M., Crowley, J.J., Coltman, C.A. and Albain Jr., K.S. (1999) Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. The New England Journal of Medicine, 341, 2061-2067. http://dx.doi.org/10.1056/NEJM199912303412706

[8]   Sobin, L.H. and Fleming, I.D. (1997) TNM Classification of Malignant Tumors, fifth Edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80, 1803-1804.

[9]   Travis, W.D., Garg, K., Franklin, W.A., Wistuba, I.I., Sabloff, B., Noguchi, M., Kakinuma, R., Zakowski, M., Ginsberg, M., Padera, R., et al. (2006) Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 1, S13-19. http://dx.doi.org/10.1097/01243894-200611001-00004

[10]   Calvert, A.H., Newell, D.R., Gumbrell, L.A., O’Reilly, S., Burnell, M., Boxall, F.E., Siddik, Z.H., Judson, I.R., Gore, M.E. and Wiltshaw, E. (1989) Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. Journal of Clinical Oncology, 7, 1748-1756.

[11]   Cockcroft, D.W. and Gault, M.H. (1976) Prediction of Creatinine Clearance from Serum Creatinine. Nephron, 16, 31-41.

[12]   Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. and Gwyther, G. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-216. http://dx.doi.org/10.1093/jnci/92.3.205

[13]   Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2001) Estimating the World Cancer Burden: Globocan 2000. International Journal of Cancer, 94, 153-156. http://dx.doi.org/10.1002/ijc.1440

[14]   Mun, M. and Kohno, T. (2008) Video-Assisted Thoracic Surgery for Clinical Stage I Lung Cancer in Octogenarians. Annals of Thoracic Surgery, 85, 406-411. http://dx.doi.org/10.1016/j.athoracsur. 2007.10.057

[15]   Cattaneo, S.M., Park, B.J., Wilton, A.S., Seshan, V.E., Bains, M.S., Downey, R.J., Flores, R.M., Rizk, N. and Rusch, V.W. (2008) Use of Video-Assisted Thoracic Surgery for Lobectomy in the Elderly Results in Fewer Complications. Annals of Thoracic Surgery, 85, 231-236. http://dx.doi.org/10.1016/j. athoracsur.2007.07.080

[16]   Gridelli, C., Perrone, F. and Monfardini, S. (1997) Lung Cancer in the Elderly. European Journal of Cancer, 33, 2313-2314. http://dx.doi.org/10.1016/S0959-8049(97)10050-8

[17]   Repetto, L. and Balducci, L. (2002) A Case for Geriatric Oncology. Lancet Oncology, 3, 289-297. http://dx.doi.org/10.1136/bmj.311.7010.899

[18]   Repetto, L., Venturino, A., Fratino, L., Serraino, D., Troisi, G., Gianni, W. and Pietropaolo, M. (2003) Geriatric Oncology: A Clinical Approach to the Older Patient with Cancer. European Journal of Cancer, 39, 870-880. http://dx.doi.org/10.1016/S0959-8049(03)00062-5

[19]   Fentiman, I.S., Tirelli, U., Monfardini, S., Schneider, M., Festen, J., Cognetti, F. and Aapro, S. (1990) Cancer in the Elderly: Why So Badly Treated? Lancet, 335, 1020-1022.
http://dx.doi.org/10.1016/0140-6736(90)91075-L

[20]   Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., Barbera, S., Ferraù, F., Piazza, E., Rosetti, F., Clerici, M., Bertetto, O., Robbiati, S. F., Frontini, L., Sacco, C., Castiglione, F., Favaretto, A., Novello, S., Migliorino, M.R., Gasparini, G., Galetta, D., Iaffaioli, R.V. and Gebbia, V. (2003) MILES Investigators. Chemotherapy for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of National Cancer Institute, 95, 362-372. http://dx.doi.org/10.1093/jnci/95.5.362

[21]   Di Maio, M., Perrone, F., Gallo, S., Iaffaioli, R.V., et al. (2003) Supportive Care in Patients with Advanced Non-Small-Cell Lung Cancer. British Journal of Cancer, 89, 1013-1021.
http://dx.doi.org/10.1038/sj.bjc.6601236

[22]   Lewis, J.H., Kilgore, M.L., Goldman, D.P., Trimble, E.L., Kaplan, R., Montello, M.J., Housman, M.G. and Escarce, J.J. (2003) Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials. Journal of Clinical Oncology, 21, 1383-1389. http://dx.doi.org/10.1200/JCO.2003.08.010

[23]   Pfister, D.G., Johnson, D.H., Azzoli, C.G., Sause, W., Smith, T.J., Baker Jr., S., Olak, J., Stover, D., Strawn, J.R., Turrisi, A.T. and Somerfield, M.R. (2004) American Society of Clinical Oncology. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. Journal of Clinical Oncology, 22, 330-353. http://dx.doi.org/10.1200/JCO.2004.09.053

[24]   The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients with Advanced Non-Small-Cell Lung Cancer. Journal of National Cancer Institute, 91, 66-72. http://dx.doi.org/10.1093/jnci/91.1.66

[25]   Gridelli, C., Cigolari, S., Gallo, C., Manzione, L., Ianniello, G.P., Frontini, L., Ferraù, F., Robbiati, S.F., Adamo, V., Gasparini, G., Novello, S. and Perrone, F. (2001) MILES Investigators. Activity and Toxicity of Gemcitabine and Gemcitabine + Vinorelbine in Advanced Non-Small-Cell Lung Cancer Elderly Patients: Phase II Data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Randomized Trial. Lung Cancer, 31, 277-284. http://dx.doi.org/10.1016/S0169-5002(00)00194-X

[26]   Fidias, P., Supko, J.G., Martins, R., Boral, A., Carey, R., Grossbard, M., Shapiro, G., Ostler, P., Lucca, J., Johnson, B.E., Skarin, A. and Lynch, T.J. (2001) A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 7, 3942-3949.

[27]   Kudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K., Shinkai, T., Sawa, T., Goto, I., Semba, H., Seto, T., Ando, M., Satoh, T., Yoshimura, N., Negoro, S. and Fukuoka, M. (2006) Phase III Study of Docetaxel Compared with Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). Journal of Clinical Oncology, 24, 3657-3663. http://dx.doi.org/10.1200/JCO.2006.06.1044

[28]   Langer, C.J. (2002) Elderly Patients with Lung Cancer: Biases and Evidence. Current Treatment Options Oncology, 3, 85-102. http://dx.doi.org/10.1007/s11864-002-0045-9

[29]   Oshita, F., Kurata, T., Kasai, T., Fakuda, M., Yamamoto, N., Ohe, Y., Tamura, T., Eguchi, K., Shinkai, T. and Saijo, N. (1995) Prospective Evaluation of the Feasibility of Cisplatin-Based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions. Japanese Journal of Cancer Research, 86, 1198-1202. http://dx.doi.org/10.1111/j.1349-7006.1995.tb03315.x

[30]   Rinaldi, M., De Marinis, F., Ardizzoni, A., et al. (1994) Correlation between Age and Prognosis in Patients with Advanced Non Small Cell Lung Cancer Treated with Cisplatin Containing Chemotherapy: A Retrospective Multicentre Study. Annals of Oncology, 58.

[31]   Kubota, K., Hosomura, K., Kakinuma, R., et al. (1998) Cisplatin Nephrotoxicity in Elderly Patients with Lung Cancer. Proceeding of the American Society of Clinical Oncology, 17, 491a.

[32]   Thyss, A., Saudes, L., Otto, J., Creisson, A., Gaspard, M.H., Dassonville, O. and Schneider, M. (1994) Renal Tolerance of Cisplatin in Patients More Than 80 Years Old. Journal of Clinical Oncology, 12, 2121-2125.

[33]   Cubillo, A., Cornide, M., López, J.L., Molina, R., Feliu, J., Espinosa, E., Zamora, P., de Castro, J., Ordo?ez, A. and González Barón, M. (2001) Renal Tolerance to Cisplatin in Patients 70 Years and Older. American Journal of Clinical Oncology, 24, 192-197. http://dx.doi.org/10.1097/00000421-200104000-00018

[34]   Nguyen, B., Sandler, A. and Denham, C. (1999) The Safety and Efficacy of Gemcitabine Plus Cisplatin in the Elderly Chemo-Na?ve NSCLC Patients (Age ≥ 70 Years) as Compared to Those with Age < 70 Years. Proceeding of the American Society of Clinical Oncology, 18, 471a.

[35]   Kelly, K., Crowley, J., Bunn, P.A., Presant Jr., C.A., Grevstad, P.K., Moinpour, C.M., Ramsey, S.D., Wozniak, A.J., Weiss, G.R., Moore, D.F., Israel, V.K., Livingston, R.B. and Gandara, D.R. (2001) Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial. Journal of Clinical Oncology, 19, 3210-3218.

[36]   Lilenbaum, R.C., Herndon, J., List, M., et al. (2002) Single-Agent (SA) vs Combination Chemotherapy (CC) in Advanced Non-Small Cell Lung Cancer (NSCLC): A CALGB Randomized Trial of Efficacy, Quality of Life (QoL), and Cost-Effectiveness. Proceeding of the American Society of Clinical Oncology, 21, 1a.

[37]   Rocha Lima, C.M., Herndon II, J.E., Kosty, M., Clamon, G. and Green, M.R. (2002) Therapy Choices among Older Patients with Lung Carcinoma: An Evaluation of Two Trials of the Cancer and Leukemia Group B. Cancer, 94, 181-187. http://dx.doi.org/10.1002/cncr.10174

[38]   Langer, C.J., Vangel, J., Schiller, D.P., et al. (2003) Age-Specific Subanalysis of ECOG 1594: Fit Elderly Patients (70-80 yrs) with NSCLC Do as Well as Younger Patients (<70). Proceeding of the American Society of Clinical Oncology, 22, 639.

[39]   Fossella, F.V. and Belani, C.P. (2003) Phase II Study (TAX 326) of Docetaxel-Cisplatin (DC) and Docetaxel-Carboplatin (DCb) versus Vinorelbine-Cisplatin (VC) for the First-Line Treatment of Advanced/Metastatic Non-Small-Cell-Lung Cancer (NSCLC): Analysis in Elderly Patients. Proceeding of the American Society of Clinical Oncology, 22, 629.

[40]   Hensing, T.A., Peterman, A.H., Schell, M.J., Lee, J.H. and Socinski, M.A. (2003) The Impact of Age on Toxicity, Response Rate, Quality of Life, and Survival in Patients with Advanced, Stage IIIB or IV Nonsmall Cell Lung Carcinoma Treated with Carboplatin and Paclitaxel. Cancer, 98, 779-788. http://dx.doi.org/10.1002/cncr.11548

[41]   Chrischilles, E.A., Pendergast, J.F., Kahn, K.L., Wallace, R.B., Moga, D.C., Harrington, D.P., Kiefe, C.I., Weeks, J.C., West, D.W., Zafar, S.Y. and Fletcher, R.H. (2010) Adverse Events among the Elderly Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 620-627. http://dx.doi.org/10.1200/JCO.2009.23.8485

[42]   Potosky, A.L., Saxman, S., Wallace, R.B. and Lynch, C.F. (2004) Population Variations in the Initial Treatment of Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 3261-3268. http://dx.doi.org/10.1200/JCO.2004.02.051

[43]   Earle, C.C., Tsai, J.S., Gelber, R.D., Weinstein, M.C., Neumann, P.J. and Weeks, J.C. (2001) Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis. Journal of Clinical Oncology, 19, 1064-1070.

[44]   Smith, T.J., Penberthy, L., Desch, C.E., Whittemore, M., Newschaffer, C., Hillner, B.E., McClish, D. and Retchin, S.M. (1995) Differences in Initial Treatment Patterns and Outcomes of Lung Cancer in the Elderly. Lung Cancer, 13, 235-252. http://dx.doi.org/10.1016/0169-5002(95)00496-3

[45]   Ramsey, S.D., Howlader, N., Etzioni, R.D. and Donato, B. (2004) Chemotherapy Use, Outcomes, and Costs for Older Persons with Advanced Non-Small-Cell Lung Cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare. Journal of Clinical Oncology, 22, 4971-4978. http://dx.doi.org/10.1200/JCO.2004.05.031

[46]   Kelly, K., Giarritta, S., Akerley, W., et al. (2001) Should Older Patient (pts) Receive Combination Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)? An Analysis of Southwest Oncology Trials 9509 and 9308. Proceeding of the American Society of Clinical Oncology, 20, 329a.

[47]   Mazzanti, P., Massacesi, C., Rocchi, M.B., Mattioli, R., Lippe, P., Trivisonne, R., Buzzi, F., De Signoribus, G., Tuveri, G., Rossi, G., Di Lullo, L., Sturba, F., Morale, D., Catanzani, S., Pilone, A., Bonsignori, M. and Battelli, T. (2003) Randomized, Multicenter, Phase II Study of Gemcitabine Plus Cisplatin versus Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer. Lung Cancer, 41, 81-89. http://dx.doi.org/10.1016/S0169-5002(03)00140-5

[48]   Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F.V., Schiller, J.H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., Bisset, D. and Rosell, R. for CISCA (CISplatin versus CArboplatin) Meta-Analysis Group (2007) Cisplatinversus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-Analysis. Journal of National Cancer Institute, 99, 847-857. http://dx.doi.org/10.1093/jnci/djk196

[49]   Lilenbaum, R.C., Herndon II, J.E., List, M.A., Desch, C., Watson, D.M., Miller, A.A., Graziano, S.L., Perry, M.C., Saville, W., Chahinian, P., Weeks, J.C., Holland, J.C. and Green, M.R. (2005) Single-Agent versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (Study 9730). Journal of Clinical Oncology, 23, 190-196. http://dx.doi.org/10.1200/JCO. 2005.07.172

[50]   Belani, C.P., Barstis, J., Perry, M.C., La Rocca, R.V., Nattam, S.R., Rinaldi, D., Clark, R. and Mills, G.M. (2003) Multicenter, Randomized Trial for Stage IIIB or IV Non-Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation. Journal of Clinical Oncology, 21, 2933-2939. http://dx.doi.org/10.1200/JCO.2003.02.563

[51]   Früh, M., Rolland, E., Pignon, J.P., Seymour, L., Ding, K., Tribodet, H., Winton, T., Le Chevalier, T., Scagliotti, G.V., Douillard, J.Y., Spiro, S. and Shepherd, F.A. (2008) Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3573-3581.

[52]   Wozniak, A.J., Crowley, J.J., Balcerzak, S.P., Weiss, G.R., Spiridonidis, C.H., Baker, L.H., Albain, K.S., Kelly, K., Taylor, S.A., Gandara, D.R. and Livingston, R.B. (1998) Randomized Trial Comparing Cisplatin with Cisplatin Plus Vinorelbine in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Study. Journal of Clinical Oncology, 16, 2459-2465.

[53]   Sandler, A.B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M.C., Gregor, A., Nguyen, B., Niyikiza, C. and Einhorn, L.H. (2000) Phase III Trial of Gemcitabine Plus Cisplatin versus Cisplatin Alone in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 18, 122-130.

[54]   Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. and Johnson, D.H. for Eastern Cooperative Oncology Group (2002) Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 346, 92-98. http://dx.doi.org/10.1056/NEJMoa011954

[55]   Gridelli, C., Langer, C., Maione, P., Rossi, A. and Schild, S.E. (2007) Lung Cancer in the Elderly. Journal of Clinical Oncology, 25, 1898-1907. http://dx.doi.org/10.1200/JCO.2006.10.3085

[56]   Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., Massidda, B., Piantedosi, F., Comella, G. and De Lena, M. (2000) Gemcitabine Plus Vinorelbine versus Vinorelbine Alone in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 18, 2529-2536.

[57]   Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. and Johnson, D.H. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550. http://dx.doi.org/10.1056/NEJMoa061884

[58]   Kubota, K., Kawahara, M., Ogawara, M., Nishiwaki, Y., Komuta, K., Minato, K., Fujita, Y., Teramukai, S., Fukushima, M. and Furuse, K. on Behalf of the Japan Multi-National Trial Organisation (2008) Vinorelbine Plus Gemcitabine Followed by Docetaxel versus Carboplatin Plus Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer: A Randomised, Open-Label, Phase III Study. Lancet Oncology, 9, 1135-1142. http://dx.doi.org/10.1016/S1470-2045(08)70261-4.

[59]   Hirabayashi, M., Endoh, K., Teramachi, M., Okuda, M., Yamaguchi, K., Fukuda, K., Tokuhisa, H., Kagioka, H., Nakai, N. and Nakade, M. (2004) Phase II Study of Carboplatin and Weekly Paclitaxel Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Kansai Clinical Oncology Group Study. Lung Cancer, 44, 355-362. http://dx.doi.org/10.1016/j.lungcan.2003.12.001

[60]   Belani, C.P., Ramalingam, S., Perry, M.C., LaRocca, R.V., Rinaldi, D., Gable, P.S. and Tester, W.J. (2008) Randomized, Phase III Study of Weekly Paclitaxel in Combination with Carboplatin versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 468-473. http://dx.doi.org/10.1200/JCO.2007.13.1912

[61]   Des Guetz, G., Uzzan, B., Nicolas, P., Valeyre, D., Sebbane, G. and Morere, J.F. (2012) Comparison of the Efficacy and Safety of Single-Agent and Doublet Chemotherapy in Advanced Non-Small Cell Lung Cancer in the Elderly: A Meta-Analysis. Critical Reviews in Oncology/Hematology, 84, 340-349. http://dx.doi.org/10.1016/j.critrevonc.2012.03.007

 
 
Top